JAHA:法洛四联症修复后中重度返流的无症状患者进行肺动脉瓣置换术是否合适?

2018-12-29 xiangting MedSci原创

在无症状性法洛四联症修复患者中进行PVR是适当的,且可以有效减少右室大小并保持右室功能。

虽然法洛四联症修复(rTOF)的症状性患者在肺动脉瓣置换术后(PVR)右心室(RV)容积显著减少,但是RV大小仍会随着RV的功能障碍而扩大。

这是一项在三级医院进行的前瞻性病例对照研究;纳入81例中重度肺动脉返流的法洛四联症修复无症状患者。纳入的队列被分为2组:PVR组(n=41)和药物组(n=40)。在入组时和PVR后、入组后6个月进行心脏磁共振、经胸超声心动图和心电图检查。记录随访期间的不良事件。随访期间药物组有3例死亡、1例心脏移植、3例PVRs和2例症状性心衰,PVR组有1例重新进行PVR。与药物组相比,PVR组的不良事件发生率显著降低(P=0.023;优势比,0.086; 95%CI,0.010-0.716),RV功能明显改善(P<0.05)。二元logistic回归分析确定了术前RV收缩末期容积指数(10-mL/m2增量,P=0.009;优势比,0.64;95%CI,0.457-0.893)是PVR后标准化RV大小的独立预测因子。PVR后标准化RV大小的ROC曲线分析的术前RV收缩末期容积指数阈值为120mL/m2(曲线下面积,0.819;敏感性,90.3%;特异性,70%)。

在无症状性法洛四联症修复患者中进行PVR是适当的,且可以有效减少右室大小并保持右室功能。推荐的PVR后标准RV 收缩末期容积指数为120mL/m2。

原始出处:

Fengpu He. Whether Pulmonary Valve Replacement in Asymptomatic Patients With Moderate or Severe Regurgitation After Tetralogy of Fallot Repair Is Appropriate: A Case‐Control Study. JAHA. 27 December 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1774465, encodeId=21901e74465c3, content=<a href='/topic/show?id=5f958205400' target=_blank style='color:#2F92EE;'>#肺动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82054, encryptionId=5f958205400, topicName=肺动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a03c38545465, createdName=cathymary, createdTime=Sun Jul 28 00:39:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808561, encodeId=9e921808561c7, content=<a href='/topic/show?id=1a6e8205e39' target=_blank style='color:#2F92EE;'>#肺动脉瓣置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82057, encryptionId=1a6e8205e39, topicName=肺动脉瓣置换)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Mon Sep 16 20:39:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742557, encodeId=29e51e42557c5, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Thu Jan 03 07:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356943, encodeId=ebef35694341, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 01 23:12:05 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268019, encodeId=b3e91268019dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421506, encodeId=ed6514215068d, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485023, encodeId=3b68148502301, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576667, encodeId=d91e15e6667d0, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1774465, encodeId=21901e74465c3, content=<a href='/topic/show?id=5f958205400' target=_blank style='color:#2F92EE;'>#肺动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82054, encryptionId=5f958205400, topicName=肺动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a03c38545465, createdName=cathymary, createdTime=Sun Jul 28 00:39:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808561, encodeId=9e921808561c7, content=<a href='/topic/show?id=1a6e8205e39' target=_blank style='color:#2F92EE;'>#肺动脉瓣置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82057, encryptionId=1a6e8205e39, topicName=肺动脉瓣置换)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Mon Sep 16 20:39:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742557, encodeId=29e51e42557c5, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Thu Jan 03 07:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356943, encodeId=ebef35694341, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 01 23:12:05 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268019, encodeId=b3e91268019dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421506, encodeId=ed6514215068d, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485023, encodeId=3b68148502301, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576667, encodeId=d91e15e6667d0, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1774465, encodeId=21901e74465c3, content=<a href='/topic/show?id=5f958205400' target=_blank style='color:#2F92EE;'>#肺动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82054, encryptionId=5f958205400, topicName=肺动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a03c38545465, createdName=cathymary, createdTime=Sun Jul 28 00:39:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808561, encodeId=9e921808561c7, content=<a href='/topic/show?id=1a6e8205e39' target=_blank style='color:#2F92EE;'>#肺动脉瓣置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82057, encryptionId=1a6e8205e39, topicName=肺动脉瓣置换)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Mon Sep 16 20:39:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742557, encodeId=29e51e42557c5, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Thu Jan 03 07:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356943, encodeId=ebef35694341, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 01 23:12:05 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268019, encodeId=b3e91268019dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421506, encodeId=ed6514215068d, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485023, encodeId=3b68148502301, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576667, encodeId=d91e15e6667d0, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-01-03 yxch48
  4. [GetPortalCommentsPageByObjectIdResponse(id=1774465, encodeId=21901e74465c3, content=<a href='/topic/show?id=5f958205400' target=_blank style='color:#2F92EE;'>#肺动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82054, encryptionId=5f958205400, topicName=肺动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a03c38545465, createdName=cathymary, createdTime=Sun Jul 28 00:39:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808561, encodeId=9e921808561c7, content=<a href='/topic/show?id=1a6e8205e39' target=_blank style='color:#2F92EE;'>#肺动脉瓣置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82057, encryptionId=1a6e8205e39, topicName=肺动脉瓣置换)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Mon Sep 16 20:39:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742557, encodeId=29e51e42557c5, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Thu Jan 03 07:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356943, encodeId=ebef35694341, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 01 23:12:05 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268019, encodeId=b3e91268019dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421506, encodeId=ed6514215068d, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485023, encodeId=3b68148502301, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576667, encodeId=d91e15e6667d0, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-01-01 orangesking

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1774465, encodeId=21901e74465c3, content=<a href='/topic/show?id=5f958205400' target=_blank style='color:#2F92EE;'>#肺动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82054, encryptionId=5f958205400, topicName=肺动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a03c38545465, createdName=cathymary, createdTime=Sun Jul 28 00:39:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808561, encodeId=9e921808561c7, content=<a href='/topic/show?id=1a6e8205e39' target=_blank style='color:#2F92EE;'>#肺动脉瓣置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82057, encryptionId=1a6e8205e39, topicName=肺动脉瓣置换)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Mon Sep 16 20:39:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742557, encodeId=29e51e42557c5, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Thu Jan 03 07:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356943, encodeId=ebef35694341, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 01 23:12:05 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268019, encodeId=b3e91268019dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421506, encodeId=ed6514215068d, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485023, encodeId=3b68148502301, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576667, encodeId=d91e15e6667d0, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2018-12-31 zhaohui6731
  6. [GetPortalCommentsPageByObjectIdResponse(id=1774465, encodeId=21901e74465c3, content=<a href='/topic/show?id=5f958205400' target=_blank style='color:#2F92EE;'>#肺动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82054, encryptionId=5f958205400, topicName=肺动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a03c38545465, createdName=cathymary, createdTime=Sun Jul 28 00:39:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808561, encodeId=9e921808561c7, content=<a href='/topic/show?id=1a6e8205e39' target=_blank style='color:#2F92EE;'>#肺动脉瓣置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82057, encryptionId=1a6e8205e39, topicName=肺动脉瓣置换)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Mon Sep 16 20:39:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742557, encodeId=29e51e42557c5, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Thu Jan 03 07:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356943, encodeId=ebef35694341, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 01 23:12:05 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268019, encodeId=b3e91268019dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421506, encodeId=ed6514215068d, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485023, encodeId=3b68148502301, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576667, encodeId=d91e15e6667d0, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1774465, encodeId=21901e74465c3, content=<a href='/topic/show?id=5f958205400' target=_blank style='color:#2F92EE;'>#肺动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82054, encryptionId=5f958205400, topicName=肺动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a03c38545465, createdName=cathymary, createdTime=Sun Jul 28 00:39:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808561, encodeId=9e921808561c7, content=<a href='/topic/show?id=1a6e8205e39' target=_blank style='color:#2F92EE;'>#肺动脉瓣置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82057, encryptionId=1a6e8205e39, topicName=肺动脉瓣置换)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Mon Sep 16 20:39:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742557, encodeId=29e51e42557c5, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Thu Jan 03 07:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356943, encodeId=ebef35694341, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 01 23:12:05 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268019, encodeId=b3e91268019dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421506, encodeId=ed6514215068d, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485023, encodeId=3b68148502301, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576667, encodeId=d91e15e6667d0, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1774465, encodeId=21901e74465c3, content=<a href='/topic/show?id=5f958205400' target=_blank style='color:#2F92EE;'>#肺动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82054, encryptionId=5f958205400, topicName=肺动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a03c38545465, createdName=cathymary, createdTime=Sun Jul 28 00:39:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808561, encodeId=9e921808561c7, content=<a href='/topic/show?id=1a6e8205e39' target=_blank style='color:#2F92EE;'>#肺动脉瓣置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82057, encryptionId=1a6e8205e39, topicName=肺动脉瓣置换)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Mon Sep 16 20:39:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742557, encodeId=29e51e42557c5, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Thu Jan 03 07:39:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356943, encodeId=ebef35694341, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 01 23:12:05 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268019, encodeId=b3e91268019dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421506, encodeId=ed6514215068d, content=<a href='/topic/show?id=068c6486e77' target=_blank style='color:#2F92EE;'>#法洛四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64867, encryptionId=068c6486e77, topicName=法洛四联症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87f3671641, createdName=tongyongming, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485023, encodeId=3b68148502301, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576667, encodeId=d91e15e6667d0, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Mon Dec 31 07:39:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]

相关资讯

Heart:成年法洛四联症患者的主动脉疾病及治疗

虽然主动脉瘤常见,但是进行性主动脉扩张并不常见。

Circ: Cardiovascular Interventions:瓣中瓣经导管肺动脉瓣置换患者生物瓣框架的目的性折断

初步经验表明,BPV框架目的性折断有助于瓣中瓣TPVR后达到更大的ID和更好的血液动力学状况。

JAMA Cardiol:法洛四联症的长期预后

单纯TOF修复后的长期生存率很好。分期修复和非瓣膜保留术与术后早期的生存率呈负相关。

Circulation:修复的法洛四联症患者肺动脉瓣置换术后死亡和室性心动过速的术前预测因子

这项针对rTOF患者的观察性研究中,PVR时年龄较大、PVR前RV肥大和功能不全可以预测短期内出现术后死亡和持续性VT。

Heart:成人心脏植入式电子设备与法洛四联症

目前的研究提供了有用的结果数据来帮助患者咨询和临床决策。需要进一步研究来探索降低设备发电机更换术后感染风险的方法。

JAHA:QRS片段在成人法洛四联症危险分层中的作用

存在重度QRS-f可用作常规临床指标的补充数据。